T. K. Owonikoko, K. P. Papadopoulos, M. L. Johnson, and E. al., “Phase 1 Study of Cemiplimab, a Human Monoclonal Anti-PD-1, in Patients with Unresectable Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC): Final Efficacy and Safety Data”, J of Skin, vol. 2, p. S78, Dec. 2018.